Literature DB >> 17950576

Antipsychotic polypharmacy does not increase the risk for side effects.

Soma Ganesan, Ross Taylor, Kiran Rabheru, Ian Forbes, Jane Dumontet, Ric M Procyshyn.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17950576     DOI： 10.1016/j.schres.2007.09.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  3 in total

Review 1.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

2.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

3.  Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program.

Authors:  Robert J Constantine; Ross Andel; Rajiv Tandon
Journal:  Community Ment Health J       Date:  2010-01-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.